Balstilimab

Generic Name: Balstilimab

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 2148321-77-9

Unique Ingredient Identifier: 1Q2QT5M7EO

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)

Phase 2

Recruiting

Conditions: Lymphoma

Interventions: Drug: Balstilimab

First Posted Date: 2023-06-07

Last Posted Date: 2023-09-28

Lead Sponsor: Immune Oncology Research Institute

Target Recruit Count: 20

Registration Number: NCT05891821

Locations: 🇦🇲
Hematology Center named after prof. R. Yeolyan, Yerevan, Armenia

Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma

Phase 2

Recruiting

Conditions: Glioblastoma, Isocitric Dehydrogenase (IDH)-Wildtype
Glioblastoma Multiforme
Gliosarcoma
Newly Diagnosed Glioblastoma

Interventions: Drug: Balstilimab
Drug: Botensilimab
Drug: Liposomal Doxorubicin
Device: Sonocloud-9 (SC-9)

First Posted Date: 2023-05-18

Last Posted Date: 2024-03-27

Lead Sponsor: Northwestern University

Target Recruit Count: 25

Registration Number: NCT05864534

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States

Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)

Phase 2

Recruiting

Conditions: Colorectal Cancer
Resectable Colorectal Carcinoma

Interventions: Drug: Trastuzumab deruxtecan
Drug: Botensilimab
Drug: Durvalumab
Drug: Panitumumab
Drug: Balstilimab
Drug: Sotorasib

First Posted Date: 2023-05-06

Last Posted Date: 2023-09-21

Lead Sponsor: Gruppo Oncologico del Nord-Ovest

Target Recruit Count: 112

Registration Number: NCT05845450

Locations: 🇮🇹
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Lombardia/MI, Italy

Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy

Phase 1

Recruiting

Conditions: Advanced Colorectal Adenocarcinoma
Advanced Microsatellite Stable Colorectal Carcinoma
Metastatic Colorectal Adenocarcinoma
Metastatic Microsatellite Stable Colorectal Carcinoma
Stage III Colorectal Cancer AJCC V8
Stage IV Colorectal Cancer AJCC V8

Interventions: Biological: Balstilimab
Procedure: Biospecimen Collection
Biological: Botensilimab
Procedure: Computed Tomography
Drug: Regorafenib

First Posted Date: 2023-01-05

Last Posted Date: 2024-08-05

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 63

Registration Number: NCT05672316

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer

Phase 2

Recruiting

Conditions: Pancreas Cancer

Interventions: Biological: TG01 Vaccine
Drug: QS-21
Drug: Balstilimab

First Posted Date: 2022-12-06

Last Posted Date: 2023-01-31

Lead Sponsor: University of Kansas Medical Center

Target Recruit Count: 24

Registration Number: NCT05638698

Locations: 🇺🇸
University of Kansas Cancer Center - Clinical Research Center, Fairway, Kansas, United States
🇺🇸
University of Kansas Cancer Center - Overland Park, Overland Park, Kansas, United States
🇺🇸
University of Kansas Cancer Center - Westwood, Westwood, Kansas, United States

and more 2 locations

A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

Phase 2

Active, not recruiting

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Standard of Care
Drug: Botensilimab
Drug: Balstilimab

First Posted Date: 2022-11-08

Last Posted Date: 2024-06-04

Lead Sponsor: Agenus Inc.

Target Recruit Count: 234

Registration Number: NCT05608044

Locations: 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸
Memorial Sloan Kettering, New York, New York, United States
🇷🇺
Branch office of " Hadassah Medical Ltd", Moscow, Russian Federation

and more 62 locations

Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)

Conditions: Cancer

First Posted Date: 2022-10-10

Last Posted Date: 2024-03-25

Lead Sponsor: Agenus Inc.

Registration Number: NCT05572970

A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

Phase 2

Active, not recruiting

Conditions: Advanced Melanoma

Interventions: Drug: Botensilimab
Drug: Balstilimab

First Posted Date: 2022-09-07

Last Posted Date: 2024-12-12

Lead Sponsor: Agenus Inc.

Target Recruit Count: 220

Registration Number: NCT05529316

Locations: 🇧🇪
Universitair Ziekenhuis Brussel, Jette, Belgium
🇪🇸
Hospital Clinic Barcelona, Barcelona, Spain
🇪🇸
Consorcio Hospital General Universitario de Valencia, Valencia, Spain

and more 46 locations

Study of AGEN1571 in Participants With Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Advanced Solid Tumor

Interventions: Drug: AGEN1571
Drug: Balstilimab
Drug: Botensilimab

First Posted Date: 2022-05-17

Last Posted Date: 2024-04-23

Lead Sponsor: Agenus Inc.

Target Recruit Count: 22

Registration Number: NCT05377528

Locations: 🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸
Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States

and more 3 locations

BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients

Phase 2

Recruiting

Conditions: HPV
Oropharyngeal Cancer

Interventions: Drug: Balstilimab

First Posted Date: 2022-05-06

Last Posted Date: 2024-05-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT05363709

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy